Hypersensitivity (including to other macrolides), severe hepatic impairment, pregnancy, breast-feeding, infant age up to 2 months.
Incompatible with ergotamine-like drugs (probably the development of ergotism and necrosis of the tissues of the extremities). Increases the absorption of digoxin, the bioavailability of omeprazole (mutually), the probability of toxic effects of theophylline, midazolam, triazolam. Displaces disopyramide from complexes with plasma proteins, increases the concentration of astemizole and pimozide in the serum (accompanied by an extension of the QT interval of the ECG or severe arrhythmias).
From the nervous system and sensory organs: dizziness, headache, weakness, malaise, impaired vision and sense of smell, tinnitus, change in taste.
From the gastrointestinal tract: abdominal pain, dyspepsia, anorexia, flatulence, nausea, vomiting, constipation or diarrhea, symptoms of pancreatitis.
Allergic reactions: rash, itching, urticaria, bronchospasm, anaphylactic shock.
Other: eczema, superinfection, oral and vaginal candidiasis.
Infections of the respiratory tract and ENT organs: tonsillitis, pharyngitis, sinusitis, diphtheria, pertussis, otitis media, SARS, chronic obstructive pulmonary diseases, bronchitis (acute and exacerbation of chronic), panbronchitis, bronchiectasis, infections of the genitourinary system (non-gonococcal urethritis, chlamydial gynecological infections), osteomyelitis, prevention of meningococcal meningitis.
Active against group A and B streptococci, resistant to beta-lactamases.
It is rapidly absorbed from the gastrointestinal tract and is detected in the plasma after 15 minutes (the presence of food slows the rate of absorption, but does not affect its completeness). Cmax it is achieved after 1.5-2 hours and at a dose of 0.15 g is 6.6 mg/l. Binding to plasma proteins-up to 96%, quickly distributed in the tissues of the respiratory tract (especially the lungs), tonsils, prostate, ovaries, kidneys, liver. When taken at a dose of 0.15 g 2 times a day, the equilibrium concentration is reached after 2-4 days. It is excreted unchanged and in the form of metabolites mainly through the gastrointestinal tract, partially by the lungs (15%), kidneys (up to 10%) and with breast milk (less than 0.05%). Average T1/2 - 10.5 hours — It does not accumulate.
In a dry place, protected from light, at a temperature not exceeding 30 °C.
Keep out of reach of children.
The shelf life of the drug Brilig®3 года.Do not use after the expiration date indicated on the package.
1 tablet, coated, contains roxithromycin 0.15 g, in a contour cell package of 10 pcs. , in a cardboard pack of 1 package.
Contraindicated. Breastfeeding should be discontinued for the duration of treatment.
Inside, before meals, adults 0.15 g 2 times a day or 0.3 g once, with severe renal insufficiency-0.15 g/day. The duration of the course is determined individually, depending on the severity of the infectious process (from 5-12 days in acute diseases of the respiratory tract and ENT organs and up to 2-2.5 months in chronic osteomyelitis). Children — 0.005-0.008 mg/kg / day in 2 doses for no more than 10 days.
J01FA06 the Roxithromycin
